NLRP3 and diabetic kidney disease: Huang H et al. [48] demonstrated the anti-inflammatory effect of cepharanthine, not only in vitro but also in vivo, by inhibiting the NLRP3 signaling pathway, thereby reducing the expression levels of the proinflammatory cytokines IL-1β and TNF-α, and alleviating diabetic nephropathy [46].